drugset

drugset / Trial / NCT02551380

Folinic Acid in Children With Autism Spectrum Disorders

NCT02551380 ↗

Phase 2 Unknown 40 enrolled Central Hospital, Nancy, France

RandomizedParallel-groupSingle-blindTreatment

Summary

The investigator planned to study the efficiency of folinic acid treatment on autistic symptoms in children suffering from autism spectrum disorder.

Timeline

Start: 2015-10
Primary completion: 2018-01
Completion: 2018-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FOLINORAL	Unknown	5 mg	—

Indications